Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povetacicept versus tacrolimus for primary membranous nephropathy
2025-521661-27-00Phase 3Authorised
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised trial in idiopathic membranous glomerulonephritis (IMG) comparing Povetacicept with Tacrolimus active control (2 arms). Primary endpoint: Complete Clinical Remission Definition 1. Planned start Dec 2025; status: authorised.
02
Drugs
povetacicepttacrolimus
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on 2025-521661-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521661-27-00.